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Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer deaths in
both men and women in the United States, carrying a 5-year survival rate of approximately
5%, which is the poorest prognosis of any solid tumor type. Given the dismal prognosis
associated with PDAC, a more thorough understanding of risk factors and genetic
predisposition has important implications not only for cancer prevention, but also for
screening techniques and the development of personalized therapies. While screening
of the general population is not recommended or practicable with current diagnostic
methods, studies are ongoing to evaluate its usefulness in people with at least 5- to
10-fold increased risk of PDAC. In order to help identify high-risk populations who would be
most likely to benefit from early detection screening tests for pancreatic cancer, discovery
of additional pancreatic cancer susceptibility genes is crucial. Thus, specific gene-based,
gene-product, and marker-based testing for the early detection of pancreatic cancer are
currently being developed, with the potential for these to be useful as potential therapeutic
targets as well. The goal of this review is to provide an overview of the genetic basis
for PDAC with a focus on germline and familial determinants. A discussion of potential
therapeutic targets and future directions in screening and treatment is also provided.
Keywords: pancreatic ductal adenocarcinoma, familiar pancreatic cancer, pancreatic cancer syndromes, pancreatic
cancer oncogenes, pancreatic cancer tumor suppressor genes
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading
cause of cancer deaths in both men and women in the United
States, carrying a 5-year survival rate of approximately 5% (Klein,
2012), which is the poorest prognosis of any solid tumor type.
Such outcomes are largely due to the fact that 80% of patients
have locally advanced or metastatic disease at diagnosis (Siegel
et al., 2013). Furthermore, for the 10–20%of patients who present
with resectable disease, the overall 5-year survival rate is only
15–20% and median survival is a dismal 18–24 months (Ducreux
et al., 2007). PDAC accounts for approximately 90% of pancreatic
neoplasms and is synonomous with the term, “pancreatic can-
cer;” the remaining 15% of pancreatic tumors are represented by
acinar cell carcinoma, pancreatoblastoma, solid pseudopapillary
neoplasm, serous cystadenoma and pancreatic neuroendocrine
tumors (Li et al., 2004a; Hezel et al., 2006; Maitra et al., 2006;
Ducreux et al., 2007). Given the dismal prognosis associated with
PDAC, a more thorough understanding of risk factors and genetic
predisposition has important implications not only for cancer
prevention, but also for development of personalized therapies.
The goal of this review is to provide an overview of the genetic
basis for PDAC with a focus on germline and familial deter-
minants, with a discussion of potential therapeutic targets also
provided.
INHERITED RISK FACTORS
Increasing knowledge of inherited genetic mutations is leading
to a better understanding of pancreatic cancer risk, as these
genetic variations are known to contribute to both familial and
non-familial (sporadic) PDAC. Studies have estimated up to 10%
of patients demonstrate an inherited predisposition to PDAC
based on familial clustering (Lynch et al., 1990, 1996; Hruban
et al., 1998; Schenk et al., 2001; Del Chiaro et al., 2007; Hruban
et al., 2010), while two prospective studies from Sweden and
Germany have suggested lower rates of 2.7 and 1.9%, respec-
tively (Hemminki and Li, 2003; Bartsch et al., 2004). A systematic
review by Permuth-Wey and Egan revealed the proportion of their
study population with a positive family history of pancreatic can-
cer was only 1.3%. In the latter study, the lower rate was attributed
to adjusting for shared environmental factors, such as smoking.
Additionally, a majority of the weight (82%) of the meta-analysis
was contributed by a prospective cohort study, as opposed to
case-control studies, which inherently pose potential for increased
biases, such as recall and publication (Permuth-Wey and Egan,
2009).
An inherited predisposition to PDAC is believed to occur in
three distinct clinical settings. Firstly, familial cancer syndromes
have a well-known association. Peutz-Jeghers Syndrome (PJS),
which is associated with germline mutations in the STK11/LKB1
gene, leads to a 36% lifetime risk for pancreatic cancer (Hahn
et al., 2003); similarly, Familial Atypical Multiple MoleMelanoma
(FAMMM) syndrome, which results due to germline mutations
in the p16/CDKN2A gene, leads to an approximate 17% lifetime
risk for pancreatic cancer (Hahn et al., 2003); other syndromes
include Hereditary Breast-Ovarian Cancer (HBOC) syndrome
(BRCA1/2 genes), Hereditary Non-polyposis Colorectal Cancer
(HNPCC; mismatch repair genes), and Familial Adenomatous
Polyposis (FAP) syndrome (APC gene) (Table 1). Secondly,
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Table 1 | Pancreatic cancer susceptibility genes.
Genes Associated Freq. of PDAC risk References
syndrome mutation (%)
ONCOGENE
BRAF 30 Maitra et al., 2006; Koorstra et al., 2008
AKT2 10–60 Koorstra et al., 2008
KRAS 30–100 Hezel et al., 2006; Koorstra et al., 2008
TUMOR SUPP
BRCA1 HBOC 2.0–2.5× Thompson et al., 2002; Hahn et al., 2003; Lynch et al., 2008; Ferrone et al., 2009
BRCA2 HBOC 3–10 3.5× Hahn et al., 2003; Koorstra et al., 2008; Lynch et al., 2008; Klein, 2012
PALB2 3–5 10–32× Jones et al., 2009; Slater et al., 2010; Schneider et al., 2011; Klein, 2012
PTEN
p16/CDKN2A FAMMM 80–95 13–22 ×17% LR Koorstra et al., 2008; Lynch et al., 2008; Bartsch et al., 2012; Klein, 2012
MMR (MLH1,2) HNPCC 4 3.7% LR Koorstra et al., 2008; Bartsch et al., 2012; Klein, 2012
APC FAP 4.5 ×<5% LR Goggins et al., 2000; Bartsch et al., 2012
TP53 Li-Fraumeni 75–85 7.3× Koorstra et al., 2008; Bartsch et al., 2012
ATM <10 2.4× Maitra et al., 2006; Koorstra et al., 2008
SMAD4/DPC4 50–60 Hezel et al., 2006; Maitra et al., 2006; Koorstra et al., 2008
STK11/KKB1 Peutz-Jeghers 35% lifetime
HBOC, hereditary breast and ovarian cancer; FAMMM, familial atypical multiple mole melanoma syndrome; FAP, familial adenomatous polyposis; LR, lifetime risk;
HNPCC, hereditary non-polyposis colorectal cancer.
hereditary causes of pancreatitis, such as the autosomal dominant
form caused by germline mutations of the cationic trypsinogen
gene, PRSS1, have been indirectly linked to PDAC through early
onset chronic pancreatitis with an associated 53-fold increased
incidence and approximately 40% of hereditary pancreatitis
patients noted to develop pancreatic cancer by age 70 (Hahn et al.,
2003; Hezel et al., 2006; Koorstra et al., 2008). Finally, Familial
Pancreatic Cancer (FPC) is defined as two or more first-degree
relatives having pancreatic cancer without fulfilling criteria for
one of the familial cancer syndromes noted above. Although at
significantly increased risk for PDAC, pancreatic cancer patients
with a hereditary predisposition have not shown any significant
difference in clinical course or median survival when compared
to sporadic pancreatic cancer patients (James et al., 2004).
FAMILIAL PANCREATIC CANCER
The presence of an inherited genetic component and possibility
of a hereditary pancreatic cancer syndrome was first suggested
by several case reports describing familial aggregation of pan-
creatic cancers (MacDermott and Kramer, 1973; Reimer et al.,
1977; Ehrenthal et al., 1987). Lynch et al performed the first sys-
tematic study of 18 families with pancreatic cancer in 1990 and
subsequent case-control and cohort studies have shown that indi-
viduals with a family history of PDAC are at an increased risk
of developing pancreatic cancer themselves (Lynch et al., 1990,
1996; Klein et al., 2001). Furthermore, the odds of having a fam-
ily history of PDAC are 1.9- to 13-fold higher in pancreatic cancer
patients compared to healthy controls (Ghadirian et al., 1991;
Jacobs et al., 2010; Klein, 2012). Jacobs et al performed a pooled
analysis of data from 5 cohort and one case-control study, which
estimated the odds of pancreatic cancer to be 1.76-fold higher
(95% CI = 1.19–2.61) among individuals with at least one first-
degree relative with PDAC compared to those without a family
history. This risk was noted to be even higher in those individuals
with at least two first-degree relatives with PDAC with an OR =
4.26 (95% CI = 0.48–37.79) (Jacobs et al., 2010). Tersmette et al
similarly noted an increased risk among those with a family his-
tory of pancreatic cancer, specifically noting that individuals with
a pair of affected first-degree relatives had an 18-fold increased
risk of developing PDAC and an estimated lifetime risk of 9–18%,
while there was an even more significant 57-fold increased risk in
FPC kindred with three or more affected family members when
compared to the SEER age-adjusted incidence of pancreatic can-
cer in the US (Tersmette et al., 2001). The National Familial
Pancreas Tumor Registry (NFPTR) has similarly concluded that
the risk of pancreatic cancer increases with the number of affected
first degree relatives (RR of 6.4 with two first-degree relatives;
32% with three first-degree relatives) (Klein et al., 2004). Based
on such conclusive findings, the clinical entity of FPC has been
defined (Tersmette et al., 2001; Hahn et al., 2003; Rulyak et al.,
2003; Brand et al., 2007; Bartsch et al., 2012; Klein, 2012).
The inheritance pattern of FPC is mostly autosomal domi-
nant and demonstrates a heterogenous phenotype (Slater et al.,
2010) The genetic mutations responsible for the majority of
clustering in families with PDAC have yet to be identified,
although germline mutations in high-penetrance genes such as
BRCA2 and PALB2 have been established along with mutations
in p16/CDKN2A, STK11/LKB1, PRSS1, BRCA1, mismatch repair
genes (hMLH1, hMSH2, hMSH6), VHL, and ATM (Table 1).
Despite sharing many of the same genetic mutations associated
with well-established familial cancer syndromes, FPC patients
must not fulfill criteria for one of the familial cancer syndromes,
and thus likely represent phenotypic variants with the associated
influence of environmental risk factors. Brand and Lynch noted
that the heterogeneity seen within pancreatic cancer cases in both
FPC and familial cancer syndromes may indeed be due to the fact
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these are similar entities that fall along a spectrum. Furthermore,
they suggested that the heterogeneity of FPC may actually lie in
the varying penetrance of the associated deleterious mutations
and the interplay of non-genetic factors, such as environmental
risk factors noted above (Brand and Lynch, 2006). The exact rela-
tionship between affected family members is also an important
indicator of risk and serves as the basis of quantitative risk mod-
eling and prediction tools, such as PancPRO, which is a Bayesian
prediction model developed at Johns Hopkins as an extension of
BRCAPRO and validated using an FPC registry with an observed-
to-predicted pancreatic cancer ratio of 0.83 (Wang et al., 2007;
Klein, 2012).
Whereas the incidence of sporadic pancreatic cancer dramat-
ically increases with age, with a peak incidence in the seventh
to eighth decade, studies examining the impact of age in FPC
patients have yielded inconclusive results. Some studies have sug-
gested a younger age of onset (8–10 years younger) in individuals
with a family history or known germline mutation (i.e., BRCA2),
while other studies have shown no association with age of onset
in those with a hereditary predisposition (Lynch et al., 1990;
Phelan et al., 1996; Ozcelik et al., 1997; Hruban et al., 1999;
Silverman et al., 1999; Lal et al., 2000; Schenk et al., 2001; Hahn
et al., 2003; James et al., 2004; Hezel et al., 2006; Brune et al.,
2010; Schneider et al., 2011; Klein, 2012). This may be explained
by epigenetic factors and the interaction between genetic and
environmental factors in the development of pancreatic cancer
(McFaul et al., 2006). This differs from the data on early-onset
breast cancer defined as less than 50 years of age, where a conclu-
sively stronger association with predisposing germline mutations,
such as BRCA1/2, is seen (Langston et al., 1996; Krainer et al.,
1997; Couch et al., 2007). Additionally, BRCA1/2 mutations car-
riers may be more likely to die from aggressive breast or ovarian
cancer at an early age, thereby masking an underlying diagnosis
of pancreatic cancer. Interestingly, the phenomenon of “antici-
pation,” which is a reduction in the age of onset of hereditary
pancreatic cancer with successive generations, has been described
in 59–85% of FPC families from studies by the European Registry
of Hereditary Pancreatitis and Familial Pancreatic Cancer and
FaPaCa (German national case collection for FPC) registries
(James et al., 2004; McFaul et al., 2006; Schneider et al., 2011).
Analysis of 80 affected child-parent pairs by McFaul et al revealed
the children died a median of 10 years earlier than the parent,
thereby providing strong implications for genetic counseling and
secondary screening per the authors (McFaul et al., 2006).
PANCREATIC CANCER SUSCEPTIBILITY GENES
The genetic basis for the majority of PDAC has yet to be dis-
covered. Although several important and high-penetrance genes
associated with increased risk of pancreatic cancer have been
identified, including BRCA2 and PALB2, it is clear that most cases
of pancreatic cancer that demonstrate familial clustering are not
explained by known genetic syndromes. This is evident by the
fact that only 10–20% of PDAC with familial aggregation results
from high-penetrance genes. Novel susceptibility genes in famil-
ial aggregating pancreatic cancer still remain to be identified in
approximately 80% of affected families, and discovery of such
genes is most likely to occur using family-based studies examining
linkage or genome-sequencing approaches (Maitra et al., 2006;
Bartsch et al., 2012; Klein, 2012).
GERMLINE MUTATIONS
Genes with germline mutations that have been identified in
FPC kindred include BRCA2 (and other Fanconi anemia DNA
repair pathway genes, including FANCC and FANCG genes),
PALB2, PTEN, STK11/LKB1, p16/CDKN2A, TP53, ATM, and
PRSS1 (Table 1). Those mutations with high-penetrance, includ-
ing BRCA2, PALB2, and PTEN, are discussed below. Notably,
genetically engineered mouse models have been created for many
of these mutations (across a wide range of malignancies), thereby
allowing for a tractable in vivo system to help determine the bio-
logic impact of oncogenic mutations as well as helping establish
genotype-phenotype relationships. Furthermore, these mouse
models have the potential to identify early markers of disease and
associated genetic mutations, as well as providing improved pre-
clinical models for therapeutic targets and initiatives (Hezel et al.,
2006).
BRCA2 (FANCONI ANEMIA DNA REPAIR PATHWAY GENE)
The BRCA2 protein is encoded by the BRCA2 gene located on
chromosome 13q and functions in the Fanconi anemia pathway,
which is partly responsible for genome-maintenance. Genomic
integrity is maintained by enabling homologous recombination
(HR)-based double-stranded (DS) DNA repair following inter-
strand crosslinking damage, in addition to acting in intra-S phase
DNA damage checkpoint control (van der Heijden et al., 2005;
Xia et al., 2006). Therefore, BRCA2 mutant cells exhibit defective
HR repair, proliferation arrest, impaired cytokinesis, radioresis-
tant DNA synthesis (due to impairment of intra-S phase DNA
damage checkpoint control), genomic instability, and hypersensi-
tivity to DNA damaging agents (e.g., PARP inhibitors, mitomycin,
platinum, etc.) (Sharan et al., 1997; Patel et al., 1998; Kraakman-
van der Zwet et al., 2002; Xia et al., 2006; Couch et al., 2007). The
majority (80%) of BRCA2 germline mutations are nonsense or
frameshift mutations, such as the 6174delT mutation and other
exon 11 mutations, which lead to the development of premature
stop codons and result in truncated and non-functional BRCA2
proteins similar to what is seen in BRCA2-mutated breast cancers
(Hahn et al., 2003). Additionally, several rare missense mutations
have been detected (Couch et al., 2007). Of note, it is estimated
that 1% of the Ashkenazi Jewish population in North America
harbors the germline BRCA2 6174delT founder mutation, which
has been associated with a 10-fold increased risk of develop-
ing pancreatic, breast, prostate, and ovarian cancers (Oddoux
et al., 1996; Ozcelik et al., 1997) Interestingly though, the BRCA2
6174delT mutation has been described to have independent
origins in both Ashkenazi Jewish and non-Jewish populations
(Berman et al., 1996; Hahn et al., 2003). BRCA2-deficient murine
models of pancreatic cancer have been established in order to
evaluate both diagnostic and therapeutic strategies for FPC. In
this setting, biallelic loss of BRCA2 alone and certainly in con-
junction with p53 deregulation, has been shown to induce the
spectrum of pancreatic ductal neoplasia although after a fairly
long latency period (Skoulidis et al., 2010; Feldmann et al., 2011;
Rowley et al., 2011). The FANCC (located on chromosome 9q)
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and FANCG (located on chromosome 9p) genes are additional
Fanconi complementation group genes which have been impli-
cated in the pathogenesis of pancreatic cancer (Goggins et al.,
1996; Maitra et al., 2006).
Previous studies analyzing families with known BRCA2 muta-
tions found young-onset breast and/or ovarian cancer BRCA2
mutation carriers to have a 3.5- to 10-fold increased risk and
estimated 5% lifetime risk of developing PDAC relative to non-
BRCA2 carriers (Breast Cancer Linkage Consortium, 1999; van
Asperen et al., 2005). Although the average age of onset of PDAC
does not differ between non-BRCA2 and BRCA2 mutated fami-
lies, it has been noted that the presence of one young-onset case of
PDAC in a pancreatic cancer family may be predictive of the pres-
ence of a BRCA2mutation (Couch et al., 2007) Additionally, it has
been suggested that BRCA2 germline mutation carriers exhibit
at least two different cancer phenotypes, although it is not yet
understood which genetic or environmental factors cause each of
these phenotypic variations, it may be due to different mutational
loci within the BRCA2 gene (Lubinski et al., 2004; Couch et al.,
2007). One phenotype demonstrates a preponderance for breast
and ovarian cancers, while a second phenotype is associated with
familial pancreatic cancer without an increased incidence of, or
high penetrance for, breast and/or ovarian cancer (Couch et al.,
2007). The overall prevalence of BRCA2 mutations in moderate-
risk (two or more affected first-degree relatives) and high-risk
(three or more affected first-degree relatives) pancreatic cancer
families, was noted by Couch et al to be approximately 6% with
a frequency ranging from 3 to 15% for families depending on the
number of affected family members (Couch et al., 2007). Other
studies have suggested the prevalence of BRCA2 germline muta-
tions to be significantly higher (12–19%) among individuals with
a family history of PDAC, albeit those specifically fulfilling crite-
ria for FPC (Murphy et al., 2002; Hahn et al., 2003). Thus, BRCA2
germline mutations are currently the most frequently identified
genetic alteration in FPC even in the absence of breast and/or
ovarian cancer (Goggins et al., 1996; Ozcelik et al., 1997; Hahn
et al., 2003).
Given that approximately 10% of high-risk FPCs are noted to
carry BRCA2-truncating mutations, it has been suggested that
these individuals undergo genetic screening for the presence of
BRCA2mutations (Couch et al., 2007). The advantages of clinical
testing include the possibility for close monitoring for pancre-
atic, as well as other BRCA2 mutation-associated cancers (breast,
ovarian, prostate) in carriers. Although prophylactic surgical
intervention to reduce the risk of breast and ovarian cancer onset
is acceptable for BRCA2 mutated female carriers from families
with numerous individuals affected with breast and/or ovarian
cancers, it is unclear whether there would be risk reduction con-
ferred by similar surgeries in women with BRCA2mutations from
families that only display a history of pancreatic cancer (Couch
et al., 2007).
BRCA1
HBOC is commonly associated with an inherited germline muta-
tion in one of the BRCA1 or BRCA2 alleles with the remain-
ing functional/wildtype allele lost via somatic mutation (Bryant
et al., 2005). As previously noted, BRCA2 mutation carriers far
outnumber BRCA1 mutation carriers in both HBOC-associated
pancreatic cancer and FPC (Hruban et al., 1999; Hahn et al.,
2003; Bartsch et al., 2012). The majority of studies examining
the prevalence of pancreatic cancer in BRCA1 mutated patients
have shown no increased risk, however, others have estimated a 2-
to 2.5-fold increased risk (Thompson et al., 2002; Ferrone et al.,
2009). Ferrone et al examined 145 Ashkenazi Jewish pancreatic
cancer patients and found no increase in frequency of BRCA1
mutations among this group (Ferrone et al., 2009). In addition,
an analysis of 66 familial pancreatic cancer patients from NFPTR
kindred with three or more relatives with PDAC did not iden-
tify any deleterious BRCA1 germline mutations in these patients
(Axilbund et al., 2009). In examining whether BRCA1 mutations
confer an increased risk of pancreatic cancer, Moran et al stud-
ied 268 British BRCA1 mutation-associated HBOC families to
determine whether BRCA-mutations conferred an increased risk
of PDAC and found no overall increased risk (Moran et al., 2012).
In addition, when specifically analyzing for the BRCA1 185delAG
founder mutation in pancreatic cancer patients, it was suggested
that BRCA1 germlinemutations do not contribute to an increased
risk of pancreatic cancer (Schnall and Macdonald, 1996).
PALB2
Germline truncating mutations in the “partner and localizer of
BRCA2” (PALB2) gene, which is located on chromosome 16p12
have been identified in approximately 3% of patients with FPC
(Jones et al., 2009; Slater et al., 2010). The PALB2 gene encodes
for a nuclear protein which co-localizes with BRCA1/2 in nuclear
foci, acts as functional bridge between the two proteins, and
provides stability to this complex by preventing proteosomal
degradation, thereby allowing it to function in HR repair and
checkpoint control as part of the Fanconi Anemia DNA repair
pathway (Xia et al., 2006). Although it appears that PALB2 allows
for stable BRCA2 association with certain nuclear structures,
PALB2 is not required for BRCA2 entry into the nucleus. Nearly
50% of nuclear bound BRCA2 is associated with PALB2 and
more than 50% of PALB2 is associated with BRCA2, as PALB2
appears to participate in only a subset of cellular responses to
DS DNA breaks. Germline BRCA2missense mutations within the
PALB2-binding motif have been shown to disrupt PALB2 bind-
ing, thereby disabling BRCA2 function, and PALB2-depleted cells
share a phenotype similar to those deficient in BRCA2 function,
further highlighting the importance of this complex (Xia et al.,
2006). Although mutated PALB2 has been linked with HBOC
syndrome and Fanconi Anemia, its role in the pathogenesis of
PDAC has only recently been shown. Indeed, according to Slater
et al, PALB2mutation carriers in FPC families demonstrated a 10-
to 32-fold increased risk for the development of pancreatic can-
cer depending on the number of affected family members (Brand
et al., 2007; Rahman et al., 2007; Jones et al., 2009; Slater et al.,
2010).
Using whole-exome sequencing to examine patients with FPC,
Jones et al identified a total of four PALB2 truncating mutations
in 3.1% of patients with pancreatic cancer (Jones et al., 2009).
While some families with PALB2 stop mutations were noted to
have a history of breast and pancreatic cancer, breast cancer was
not seen in all families (Jones et al., 2009; Slater et al., 2010).
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Further studies have identified additional PALB2 mutations in
1–3% of FPC kindred (Tischkowitz et al., 2009; Slater et al., 2010).
Nonsense and frameshift mutations, particularly in exon 11 of
the PALB2 gene, result in a variety of premature stop codons and
ultimately a truncated PALB2 protein, which is exceedingly rare
in the general population and those without cancer (Slater et al.,
2010). Additionally, while some studies have suggested an earlier
age of onset of pancreatic or breast cancer in those with PALB2
mutations in the setting of FPC, recent studies have not observed
similar findings (Slater et al., 2010).
PTEN
Phosphatase and tensin homolog (PTEN) is a major tumor sup-
pressor gene located on chromosome 10q, which encodes a reg-
ulator of the NF-kB cytokine network in PDAC. It specifically
inhibits activated PI3K (phosphoinositide-3-kinase) and forma-
tion of its enzymatic product, phosphorylated phosphatidyli-
nositides (PIP3) (Koorstra et al., 2008). Whereas initiation of
PDAC tumorigenesis has been found to be driven by oncogenic
KRAS mutations, disease progression has been associated with
frequent loss of tumor suppressors within tumor cells, such as
the PI3K/PTEN pathway. Possibly due to promoter hyperme-
thylation, aberrant expression and deletion of the PTEN gene
has been frequently noted in primary tumor tissue (Asano
et al., 2004). Furthermore, the PI3K/PTEN pathway has been
reported to be activated in PDAC precursor lesions via acti-
vating mutations of PIK3CA, which is the gene that encodes
PI3K (Schonleben et al., 2006; Koorstra et al., 2008). Even in
the absence of such mutations, it has been observed that the
PI3K/AKT pathway is constitutively activated in the majority
of pancreatic cancers, through aberrant expression of PTEN as
well as amplification or activation of AKT2 kinase (Cheng et al.,
1996; Ruggeri et al., 1998; Schlieman et al., 2003; Asano et al.,
2004; Reichert et al., 2007; Koorstra et al., 2008). In mouse
models, PDAC is driven by combined oncogenic KRAS muta-
tion and haploinsufficient PTEN deficiency, which together pro-
mote marked NF-kB activation, its cytokine network (CCL20,
CXCL1, IL-6, and IL-23), stromal activation, and immune cell
infiltration; these processes shape the pancreatic cancer tumor
microenvironment, stimulate the development of peritumoral
stroma, and promote local andmetastatic progression (Ying et al.,
2011). The desmoplastic host response is a hallmark patho-
logic feature of pancreatic cancer and is characterized by the
aforementioned peritumoral stroma consisting of fibroblasts and
inflammatory cells. This process is felt to be partly mediated
by increased TGF- β levels, and contributes to the decreased
tumor vascular density which in turn is felt to compromise
delivery of systemic agents and promote radioresistance through
hypoxia. As a result, stromal targeting agents are currently under
active clinical investigation in patients with locally advanced and
metastatic pancreatic cancer (Hezel et al., 2006; Ying et al., 2011).
Moreover, constitutively-activated NF-kB and correspondingly
upregulated PI3K/AKT signaling have been observed inmany pri-
mary PDAC cell lines, but not in normal pancreatic tissue speci-
mens suggesting angiogenesis-based pro-survival mechanisms via
VEGF, urokinase, and other proinvasive/angiogenic factors (Hezel
et al., 2006). Furthermore, activated NF-kB is hypothesized
to contribute to pancreatic tumor chemoresistance via upreg-
ulation of BCL-2, BCL-XL, and other anti-apoptotic proteins
(Hezel et al., 2006).
CARCINOGENESIS AND SOMATIC MUTATIONS
The genetic progression model for PDAC, comparable to that
of the adenoma-carcinoma sequence seen in colorectal cancer,
results from sequential acquisition of mutations in the proto-
oncogene KRAS followed by mutations in tumor suppressor
genes such as p16/CDKN2A/INK4A, TP53, and SMAD4 that
lead to disturbance in cell cycle regulation, and promote the
PanIN-to-PDAC progression (Hruban et al., 2000; Schneider
and Schmid, 2003). The noninvasive pancreatic intraepithelial
neoplasia (PanIN) lesion may harbor many of the same muta-
tions found in invasive PDAC, although there are likely to be
an increasing number of mutations associated with increasing
degrees of dysplasia within the PanIN (Hruban et al., 2000).
The major genetic alterations leading to sporadic pancreatic can-
cer are thought to be mutations in the proto-oncogene, KRAS,
as well as the p16/CDKN2A/INK4A, TP53, and DPC4/SMAD4
tumor suppressor genes, while mutations in BRCA2, the mis-
match repair genes (hMLH1, hMSH2, and hMSH6), and the
AKT2 and STK11/LKB1 genes are noted to be rare (Schneider
and Schmid, 2003; Hezel et al., 2006). Since p16/CDKN2A and
BRCA2mutations are not detected in the earliest sporadic prema-
lignant pancreatic lesions and are more commonly found in later
intermediate and advanced PanIN lesions, supports the hypothe-
sis that these changes likely accumulate and impact the malignant
progression of precursor lesions into PDAC rather than partici-
pate in cancer initiation (Hezel et al., 2006). It is likely that the rel-
ative late event of biallelic loss of BRCA2 in PDAC tumorigenesis
is similar and shared between PDAC in those with germline and
somatic mutations in the BRCA2 gene (Goggins et al., 2000; Hezel
et al., 2006). KRAS gene mutations occur first in the lowest grade
of intraductal lesions, known as PanIN-1 and are subsequently
followed by p16/CDKN2A gene mutations, which are noted in
PanIN-2 (moderately advanced/intermediate grade) lesions; the
TP53, SMAD4, and sporadic BRCA2 inactivating mutations are
not identified until further progression to a PanIN-3 (high grade)
lesion (Hruban et al., 2000; Hezel et al., 2006). Knowledge of the
underlying molecular mechanisms involved in pancreatic cancer
tumorigenesis will offer new diagnostic and therapeutic options
for the treatment and early detection of PDAC and its precursor
lesions.
ONCOGENES
Mutated, constitutively activated oncogenes contribute to onco-
genesis in PDAC, and include KRAS, BRAF, AKT2, and AIB I
(Table 1) (Maitra et al., 2006).
KRAS
PDAC harbors the highest incidence of mutations in RAS pro-
teins, which are known to mediate pleiotropic effects, includ-
ing cell proliferation, differentiation, survival, and migration
via GTP-binding cytoplasmic protein activity (Schneider and
Schmid, 2003; Hezel et al., 2006). Oncogenic KRAS, located on
chromosome 12p, is one of the most frequently mutated genes in
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PDACwith over 90% of tumors harboring a KRAS gene mutation
(Hruban et al., 1993; Maitra et al., 2006). The vast majority of the
KRAS activating point mutations occur at codon 12 and less fre-
quently at codons 13 and 61, thereby resulting in a constitutively
activated protein product and downstream stimulatory signals
to RAS effector pathways, such as RAF-mitogen-activated pro-
tein (MAP) kinase, PI3K, and RalGDS pathways independent of
growth factor stimulation (Hruban et al., 1993; Hezel et al., 2006;
Maitra et al., 2006; Koorstra et al., 2008). These mutations appear
to occur very early in the development of pancreatic neoplasia,
as evidenced by the presence of KRAS mutations in noninva-
sive precursor lesions, including intraductal papillary mucinous
neoplasms (IPMN) and PanINs (Hezel et al., 2006; Maitra et al.,
2006). KRAS mutations are the first known genetic alterations
known to occur sporadically in normal pancreatic tissue, chronic
pancreatitis, and smokers; moreover, they are detected in approx-
imately 30% of early pancreatic neoplasms and close to 100% of
advanced PDAC lesions. KRAS-mediated oncogenesis has thus
been considered a likely necessary event in the development of
PDAC (Rozenblum et al., 1997; Hezel et al., 2006). Biomarker
studies have suggested KRAS activation alone is unlikely to single-
handedly promote carcinogenesis given the finding of oncogenic
KRAS in normal tissues, such as lung, pancreas and colon (Lu
et al., 2002). Follow up murine studies have suggested a thresh-
old level of oncogenic KRAS expression is required to initiate
transformation through downstream activation of KRAS-effector
genes (Ardito et al., 2012; di Magliano and Logsdon, 2013).
Although KRAS has been considered an attractive therapeutic
target, its specific biochemical properties have made it an elu-
sive target. Oncogenic mutations in KRAS result in a decreased
intrinsic rate of GTP hydrolysis and make the molecule insen-
sitive to GTPase activating proteins (GAPs) (Hezel et al., 2006).
These oncogenic mutations inhibit the protein’s enzymatic activ-
ity; thus, an effective KRAS inhibitor would increase the GTPase
activity or make the KRAS protein more susceptible to GAPs
(Hezel et al., 2006). This differs from the traditional paradigm of
attempting to inhibit an oncogene’s enzymatic function.
The mammalian Hedgehog family of secreted signaling pro-
teins (Shh, Ihh, and Dhh) regulate the embryonic growth and
patterning of many organs, including the pancreas. Activating
mutations in Hedgehog proteins have been associated with a
variety of cancers. Hedgehog pathway activation, specifically
the overexpression of the pathway’s principal activating ligand,
sonic hedgehog (Shh), has been implicated in both the initia-
tion and maintenance of pancreatic ductal neoplasia as well as
more advanced lesions with a relative increase in the expression
of Hedgehog ligands observed during pancreatic ductal tumori-
genesis. This increased expression of ligands differs from the
undetectable expression of Hedgehog ligands in normal human
pancreatic ducts. Furthermore, it has been confirmed that the
Hedgehog pathway also plays a role in metastases, with inhibi-
tion of Hedgehog signaling shown to reduce the incidence of
systemicmetastasis seen in PDAC xenografts (Berman et al., 2003;
Maitra et al., 2006; Koorstra et al., 2008). Studies in pancre-
atic cancer cell lines have revealed crosstalk between oncogenic
KRAS and the Hedgehog signaling pathway, which may suggest
oncogenic KRAS plays an important role in activating Hedgehog
signaling through the RAF/MEK/MAPK pathway in the absence
of Hedgehog ligands during pancreatic tumorigenesis (Koorstra
et al., 2008).
BRAF
The BRAF gene found on chromosome 7q encodes a ser-
ine/threonine kinase, which is regulated by binding to RAS and
also functions in the RAS-RAF-MEK-ERK-MAP kinase pathway
(Koorstra et al., 2008). It is mutated in 1/3 of pancreatic cancers
with known wild-type KRAS (Calhoun et al., 2003; Maitra et al.,
2006; Koorstra et al., 2008). Thus, KRAS and BRAF oncogenes
may function in a mutually exclusive manner in the transfor-
mation and carcinogenesis of pancreatic cancers; indeed, some
studies suggest that a mutation in one of these two genes invari-
ably results in retention of wild-type copies of the other (Maitra
et al., 2006; Koorstra et al., 2008). This suggests a potential
requirement for either oncogenic KRAS or BRAF-related signal
transduction as a critically important step in the malignant trans-
formation of most pancreatic tumors, and also implies that the
RAF-MAP signaling pathway plays a critical role in mediating
cancer-causing signals in the RAS pathway (Maitra et al., 2006;
Koorstra et al., 2008).
AKT2
The AKT2 gene is located on chromosome 19q and encodes a
serine-threonine kinase that acts as a downstream effector of the
PI3K/AKT pathway. This gene is amplified and overexpressed in
approximately 10–60% of PDAC (Ruggeri et al., 1998; Schneider
and Schmid, 2003; Hezel et al., 2006; Koorstra et al., 2008). It can
be activated by epidermal growth factor, platelet-derived growth
factor, and basic fibroblast growth factor, all of which are known
to be overexpressed in pancreatic cancer, as well as through the
PI3K/AKT pathway (Friess et al., 1996; Schneider and Schmid,
2003; Hezel et al., 2006; Koorstra et al., 2008). AKT signaling has
also been linked to enhanced insulin-like growth factor I receptor
(IGF-IR) expression in PDAC by promoting invasive potential of
cells (Tanno et al., 2001; Schneider and Schmid, 2003; Hezel et al.,
2006).
AIB I
Located on chromosome 20q, the AIB I gene is amplified in
as many as 60% of PDAC. The nuclear receptor coactivator,
Amplified In Breast cancer 1 (AIB I/SRC-3), belongs to the
p160/steroid receptor coactivator family (SRC) (Koorstra et al.,
2008). AIB I amplification and overexpression are not only
detected in hormone-sensitive tumor types, such as breast, ovar-
ian, and prostate cancers, but also in nonsteroid-targeted tumors
including colorectal, hepatocellular, and pancreatic cancers
(Koorstra et al., 2008).
TUMOR SUPPRESSOR GENES
Tumor suppressor genes are recessive and promote tumor growth
when inactivated. Loss of function of several tumor suppres-
sor genes has been observed in PDAC. Biallelic inactivation
of these genes can occur via several mechanisms, including
intragenic mutation of one allele coupled with loss of the sec-
ond allele (loss of heterozygosity mutations), deletion of both
Frontiers in Physiology | Gastrointestinal Sciences March 2014 | Volume 5 | Article 87 | 6
Reznik et al. Genetics and targets of PDAC
alleles (homozygous deletion), or hypermethylation of the gene’s
promotor resulting in silencing of gene expression. The most
common tumor suppressor genes noted to be inactivated in
greater than half of all PDAC are p16INK4A/CDKN2A, TP53,
and SMAD4/DPC4 (Table 1). BRCA2, which is inactivated less
frequently (7%), is discussed above (Rozenblum et al., 1997;
Hahn and Schmiegel, 1998; Maitra et al., 2006; Koorstra et al.,
2008).
P16INK4A/CDKN2A
The p16INK4A/CDKN2A (cyclin-dependent kinase inhibitor 2A)
tumor suppressor gene is located on chromosome 9p and encodes
the p16INK4A protein, which regulates the cell cycle through the
p16/Rb pathway and controls progression through the G1/S tran-
sition. Subsequent inhibition of the cyclin D1/CDK4/6 kinase
complex results in inappropriate phosphorylation of Rb and
blocks entry into S phase of the cell cycle (Schneider and Schmid,
2003; Hezel et al., 2006). Although germline and sporadic muta-
tions have been identified with carriers of the germline p16-
Leiden mutation, having an estimated 17% risk of developing
pancreatic cancer by the age of 75, CDKN2A has been identi-
fied as one of the most frequently inactivated somatic tumor
suppressors in PDAC (Koorstra et al., 2008). Inactivation of the
gene during sporadic mutation occurs via homozygous deletion
in 40% of cases, loss of heterozygosity in 40%, and gene inacti-
vation through promotor hypermethylation in 15–20% (Caldas
et al., 1994; Rozenblum et al., 1997; Maitra et al., 2006; Koorstra
et al., 2008). p16INK4A/CDKN2A mutations cooperate with
KRAS mutations in the development of PDAC, and are known
to accelerate tumor progression in the setting of concurrent p53
mutations (Hezel et al., 2006).
Germline mutations in exon 1α of the p16INK4A/CDKN2A
gene are associated with FAMMM syndrome (Gruis et al.,
1995; Schneider and Schmid, 2003). In addition to a signifi-
cantly increased risk of developing melanoma, individuals with
FAMMM syndrome have a 20- to 34-fold increased risk of devel-
oping PDAC, although the penetrance is much lower potentially
suggesting a modulating role by environmental factors (Hahn
et al., 2003; Schneider and Schmid, 2003; Hezel et al., 2006;
Maitra et al., 2006). Homozygous deletions resulting in inactiva-
tion of the p16INK4A/CDKN2A gene also frequently inactivate
an adjacent gene on chromosome 9p, MTAP (methylthioadeno-
sine phosphorylase), which is located 100 kilobases telomeric and
plays an important role in the synthesis of adenosine. As a result
of this coincident inactivation, MTAP function is completely lost
in approximately 30% of PDAC and is also under active investi-
gation as a potential therapeutic target using purine biosynthesis
inhibitors, such as L-alanosine (Hustinx et al., 2005; Maitra et al.,
2006; Koorstra et al., 2008). It has been suggested that use of such
a targeted agent may be effective against the 1/3 of PDACs that
harbor the deletion of this adjacent gene (Hustinx et al., 2005;
Maitra et al., 2006; Koorstra et al., 2008).
TP53
The p53 protein is encoded by the TP53 gene located on chro-
mosome 17p and is responsible for modulating cellular responses
to cytotoxic stress by maintaining genomic stability. Specifically,
p53 is responsible for regulation of the G1/S cell cycle check-
point, maintenance of G2/M arrest, induction of apoptosis, and
protection against genomic rearrangement and accumulation of
mutations. It also suppresses cellular transformation caused by
oncogenic activation or loss of tumor suppressor pathways; thus,
deletion or inactivation of TP53 is associated with aneuploidy, as
well as the growth and survival of cells harboring chromosomal
aberrations and genetic instability with potential for carcinogenic
transformation (Schneider and Schmid, 2003; Hezel et al., 2006;
Maitra et al., 2006; Koorstra et al., 2008). The loss of p53 function
results in deregulation of two essential controls over cell num-
ber, cell proliferation, cell division and cell death (Schneider and
Schmid, 2003; Hezel et al., 2006). Notably, TP53 inactivation is
the most common somatic alteration in human cancer, has been
described in Li-Fraumeni syndrome, and is inactivated in 75–85%
of PDAC almost always via intragenic mutation coupled with a
somatically acquired loss of the second allele (Redston et al., 1994;
Rozenblum et al., 1997; Schneider and Schmid, 2003; Hezel et al.,
2006).
Additionally, p53-induced growth arrest is achieved by trans-
activation of p21. Binding of p53 to DNA stimulates p21 protein
production, which negatively regulates the cyclin D/CDK2 com-
plex and prevents the cell from progressing through G1-S phase.
This process also allows time for damaged DNA to be repaired.
However, mutated p53 is unable to bind DNA, p21 is not avail-
able, and abnormal and deregulated growth occurs as a result.
Loss of p21 activity through lack of transactivation has been
observed in approximately 30–60%of PDAC specimens (Koorstra
et al., 2008).
SMAD4
The SMAD4 gene, also known as DPC4 (deleted in pancreatic
carcinoma, locus 4) is located on chromosome 18q21 and is inac-
tivated in approximately 50–60% of PDAC (Hezel et al., 2006;
Maitra et al., 2006; Jones et al., 2008). In 30–35% of the tumors,
the gene is inactivated by homozygous deletion and by a loss of
heterozygosity mutation in another 20–30% of cases. The pro-
tein product of the SMAD4 gene functions in transcriptional
regulation and localizes to the nucleus following activation of
the TGF-β intracellular signaling cascade (Derynck and Zhang,
2003; Hezel et al., 2006; Maitra et al., 2006). Once Smad4 is in
the nucleus, it exhibits growth-controlling effects by regulating
expression of specific gene targets (Maitra et al., 2006). Loss of
SMAD4 interferes with the intracellular signaling cascades down-
stream from TGF-β, resulting in decreased growth inhibition via
loss of pro-apoptotic signaling or via inappropriate G1/S tran-
sition (Koorstra et al., 2008). Although it is assumed that the
growth-inhibitory function of TGF-β is important in SMAD4
tumor suppressor activity, data has also suggested a TGF-β inde-
pendent function of SMAD4, which modulates the interaction of
the tumor with the microenvironment. This includes a decrease
in pro-angiogenic VEGF expression and an increase in angiogen-
esis inhibitor TSP-1 (Schneider and Schmid, 2003). Thus, SMAD4
tumor suppressor function may also occur through regulation of
an angiogenic mechanism (Schneider and Schmid, 2003; Hezel
et al., 2006). Frequent inactivation of the SMAD4 gene appears
to be specific to PDAC, as inactivation is rarely noted in other
www.frontiersin.org March 2014 | Volume 5 | Article 87 | 7
Reznik et al. Genetics and targets of PDAC
tumor types or in non-ductal neoplasms of the pancreas (Maitra
et al., 2006; Koorstra et al., 2008). Immunohistochemical staining
for the Smad4 protein on tissue sections correlates strongly with
SMAD4 gene status; thus, immunostaining can be used diagnos-
tically to determine SMAD4 gene status in biopsies and resected
tissues, as well as to suggest a pancreatic primary in the setting
of occult metastatic adenocarcinoma (Wilentz et al., 2000; Maitra
et al., 2006; Koorstra et al., 2008). This is particularly useful since
PDAC with loss of Smad4 reportedly demonstrate an increased
propensity for distant metastases and thus have a generally poorer
prognosis, although SMAD4 gene status is not yet utilized for
prognostic stratification (Schneider and Schmid, 2003; Blackford
et al., 2009).
STK11/LKB1 AND OTHER TUMOR SUPPRESSOR GENES
Genetic alterations in tumor suppressor genes found in lower
frequency (<10%) in pancreatic cancer include STK11/LKB1,
MKK4, TGFβR1 (ALK 5, chromosome 9q), TGFβR2 (chromo-
some 3p), ACVR1β (ALK 4, chromosome 12q), ACVR2 (chro-
mosome 2q), FBXW7 (CDC4), EP300, BRCA2, ATM, and AKT2
(Maitra et al., 2006; Koorstra et al., 2008). These infrequently
mutated genes provide further insight into cellular pathways
altered in PDAC, as well as potential therapeutic targets for gene-
specific therapies (Maitra et al., 2006). The STK11/LKB1 gene
on chromosome 19p13 encodes for a serine/threonine kinase
that regulates cell polarity and metabolism (Jenne et al., 1998;
Schneider and Schmid, 2003; Hezel et al., 2006). Inactivation of
the STK11 gene appears to play a role in both hereditary and
sporadic PDAC (Schneider and Schmid, 2003; Hezel et al., 2006).
Germline mutations in this gene are associated with PJS and are
identified in approximately 50% of PJS families who typically
present with hamartomatous polyps of the GI tract, pigmented
macules of the lips and buccal mucosa, as well as a 36% lifetime
risk for the development of pancreatic cancer (>40-fold increased
RR) (Giardiello et al., 2000; Sato et al., 2001; Hahn et al., 2003;
Hezel et al., 2006). Somatic STK11 mutations have been observed
in approximately 5% of sporadic PDAC, particularly those that
arise in association within an IPMN, whereas loss of heterozygos-
ity is seen in approximately 25% of patients with IPMN who lack
PJS features (Sato et al., 2001; Hezel et al., 2006).
In a smaller percentage of PDAC, intragenic mutations and
homozygous deletions of the MKK4 gene are noted. This gene
encodes for a component of a stress-activated protein kinase cas-
cade and functions in apoptosis and growth control (Koorstra
et al., 2008). MKK4 is preferentially inactivated in specific sub-
sets of pancreatic cancer metastases and less commonly in the
primary tumors of the same patients (Xin et al., 2004; Koorstra
et al., 2008). Thus, it has been suggested that the MKK4 protein
product may function as a suppressor of metastasis in pancre-
atic cancer, as it is does in breast and prostatic carcinomas (Xin
et al., 2004). There is also a noted trend toward worse survival
in those patients with loss of MKK4 expression and thus eval-
uation of MKK4 immunolabeling may have prognostic value.
Furthermore, there lies the potential forMKK4 to be a therapeutic
target for restoration of the stress-activated protein kinase path-
way in advanced PDAC patients (Xin et al., 2004; Koorstra et al.,
2008).
BIOMARKERS AND THERAPEUTIC TARGETS
A better understanding of the genetic causes of sporadic and FPC
has afforded the opportunity to investigate novel mechanism-
based targeted and systemic therapies, as well as predictive and
prognostic biomarkers.
TARGETING DNA REPAIR
BRCA1/2, other Fanconi anemia family proteins, and PARP-1/2
among others, function in a coordinated series of early events in
DNA damage repair. When this process is impaired, cells become
exquisitely sensitive to DNA damaging agents. The potential to
exploit this strategy exists in PDAC. Mitomycin C is an alky-
lating antineoplastic agent that works by inducing interstrand
DNA crosslinking with eventual production of DS-breaks. Early
xenograft studies by van der Heijden et al showed a more pro-
nounced response of FANCC and BRCA2-deficient pancreatic
tumors to mitomycin C relative to Fanconi anemia proficient
xenografts (van der Heijden et al., 2005). This enhanced pre-
clinical response to mitomycin C involved cell cycle arrest in
late S or G2/M phase and caspase-dependent apoptosis; simi-
lar findings were noted with cyclophosphamide, another DNA
interstrand crosslinking agent (van der Heijden et al., 2005). In
spite of such promising preclinical data, clinical results with both
mitomycin C and cyclophosphamide have been disappointing.
In a retrospective analysis by Brunner et al, the combination
of 5-fluorouracil and mitomycin C-based chemoradiotherapy
demonstrated worsemedian overall survival (9.7 vs. 12.7months)
and 1 year overall survival (53 vs. 40%) compared to gemc-
itabine and cisplatin-based chemoradiotherapy in patients with
locally advanced PDAC with similar toxicities. (Brunner et al.,
2011). A phase II study by Cereda et al looking at salvage therapy
with mitomycin C and ifosfamide (analog of cyclophosphamide)
in gemcitabine-resistant metastatic pancreatic cancer was closed
prematurely based on poor clinical outcomes with 71% of
patients experiencing chemotherapy interruption due to progres-
sive disease and 80% of patients demonstrating grade>2 toxicity.
This study concluded that the mitomycin C and ifosfamide regi-
men was considered insufficiently active in gemcitabine-resistant
metastatic pancreatic cancer (Cereda et al., 2011).
Poly (ADP-ribose) polymerase-1/2 (PARP-1/2) activity and
poly (ADP-ribose) polymerization are essential for the repair of
single stranded (SS)-DNA breaks through the base excision repair
(BER) pathways (Bryant et al., 2005). Additionally, enhanced
PARP-1 expression is seen in many tumor types compared to
normal cells, and represents one of the mechanisms by which
tumors avoid apoptosis caused by DNA damaging agents (Berger
et al., 1978). In the absence of PARP-1, spontaneous SS-breaks
can collapse replication forks and trigger HR repair (Bryant et al.,
2005). Despite its role in cellular responses to genotoxic stress,
in knockout mouse models, PARP-1 has been shown to not be
required for survival or fertility in the absence of such insults;
thus, PARP-1 can be considered a non-essential DNA repair pro-
tein in the setting of functional HR repair mechanisms (Bryant
et al., 2005). Inhibition of PARP is therefore known to sen-
sitize tumor cells to cytotoxic agents, such as topoisomerase-I
inhibitors and alkylators, which induce DNA damage normally
repaired by BER. The resulting increase in HR repair that occurs
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in PARP-1 deficient mice is felt to represent an error-free mecha-
nism, which likely explains why the genetic instability in PARP-1
deficient cells is not associated with accumulation of mutations or
cancers (Bryant et al., 2005). BRCA2 and other Fanconi Anemia-
pathway defective cells are felt to be sensitive to single-agent PARP
inhibition and restoring functional BRCA abrogates this activity.
(Bryant et al., 2005). Therefore, compromise of both BER and HR
repair is felt to result in a lethal persistence and accumulation
of recombinogenic lesions, chromosomal instability, cell cycle
arrest, and resulting apoptosis partly through use of alternative
error-prone repair pathways, such as SS annealing and non-
homologous end joining (NHEJ) (Farmer et al., 2005). Bryant et
al demonstrated that PARP inhibitors were profoundly cytotoxic
to a BRCA2-deficient cell line at low concentrations relative to
BRCA2-competent cells and normal cells, thus suggesting poten-
tial for a wide therapeutic index (Bryant et al., 2005). Whereas
clonogenic survival was significantly reduced following PARP-1
and BRCA2 protein co-depletion in human cells using siRNA,
depletion of PARP-2 with BRCA2 had no effect on clonogenic
survival following treatment with PARP inhibitors. Depletion of
PARP-2 in PARP-1- and BRCA2-depleted cells also did not result
in added toxicity. Thus, it has been suggested that PARP-1, rather
than PARP-2, is responsible for protection against spontaneously
occurring recombinogenic lesions in cells. In turn, these lesions
may convert to persistent DS breaks and collapsed replication
forks during replication, which may ultimately result in cellu-
lar apoptosis in the absence of PARP-1-mediated repair (Bryant
et al., 2005). Preclinical studies have demonstrated the potential
effectiveness of PARP inhibitors in targeting pancreatic cancers
demonstrating biallelic inactivation of the ATM gene and clini-
cal trials are underway investigating the role of PARP-inhibition
with DNA damaging agents in patients with or without BRCA-
mutations (NCT01908478, NCT01585805) (Williamson et al.,
2012).
HEDGEHOG SIGNALING PATHWAY INHIBITION
Aberrant activation of previously quiescent developmental signal-
ing pathways, such as the Hedgehog pathway has been implicated
in PDAC tumorigenesis, progression and development of metas-
tases (Koorstra et al., 2008). Targeting of sonic hedgehog, the
overexpressed principal activating ligand of the Hedgehog sig-
naling pathway, has been a focus of much investigation (Berman
et al., 2003; Maitra et al., 2006). Drugs such as cyclopamine have
been developed which specifically inhibit the hedgehog path-
way, thereby producing dramatic anti-tumor effects in murine
xenograft PDAC models without significant side effects (Berman
et al., 2003; Maitra et al., 2006). Given the dramatic results seen
with cyclopamine, development of additional inhibitors of the
hedgehog pathway, such as IPI-926 and GDC-0449, have and
continue to be explored in clinical studies in the treatment of both
pancreatic and other solid tumors with varied responses noted
thus far (Berman et al., 2003; Maitra et al., 2006; Kelleher, 2011;
LoRusso et al., 2011). One such study by Olive et al, examined
the addition of IPI-926 to gemcitabine applied in a genetically
engineered pancreatic cancermouse model, which demonstrated
a significant depletion of tumor-associated stroma and a corre-
sponding increased intratumoral concentration of gemcitabine
(Olive et al., 2009). Unfortunately, a follow-up double blind,
placebo-controlled phase II study randomizing patients with pre-
viously untreated metastatic pancreatic cancer to gemcitabine
with or without IPI-926 (saridegib) was discontinued following
interim analysis due to inferior survival of the investigational
arm. As a result, clinical excitement over hedgehog inhibition
has waned. Additionally, given the relationship between the
RAS/MAPK and Hedgehog signaling pathways in PDAC, it has
been suggested that synergistic targeting of both the RAS and
Hedgehog pathways may represent a new therapeutic strategy for
the treatment of PDAC (Pasca di Magliano et al., 2006; Koorstra
et al., 2008; Mimeault and Batra, 2010; LoRusso et al., 2011).
KRAS AND BEYOND
Benzodiazepine peptidomimetics have been shown to block the
post-translational attachment of farnesyl groups to Ras proteins,
which are required for attachment to the cellular membrane.
In preclinical studies, such farnyltransferase inhibitors restored
normal growth patterns to Ras-transformed cells suggesting ther-
apeutic potential in PDAC (James et al., 1993). However, when
this was examined in a Phase III clinical study, the addition of tip-
ifarnib (farnyltransferase inhibitor) to gemcitabine in advanced
pancreatic cancer did not demonstrate any improvement in over-
all, 6-month, and 1-year survivals over gemcitabine alone, with
acceptable toxicity noted in both arms (Van Cutsem et al., 2004).
Based on the significant clinical benefit noted in patients with
locally advanced disease, it was suggested that the negative results
of this study could be explained by 76% of the patients in the
study having metastatic disease and correspondingly large tumor
burdens (Van Cutsem et al., 2004). As noted previously, tumors
with oncogenic KRAS are often associated with relative drug
resistance and poor prognosis (Hezel et al., 2006; Barbie et al.,
2009). Thus, the combination of oncogenic KRAS mutation with
PTEN-deficiency seen in PDAC promote NF-kB activation and
sustained activity of the NF-kB downstream cytokine pathway.
This is mediated via an elevated PI3K pathway, which provides
yet an additional avenue for targeted therapies for those tumors
demonstrating altered PI3K regulation (Ying et al., 2011).
Targeting of KRAS effectors such as mTOR, which act down-
stream of AKT2 have previously been shown to be activated in
PDAC. Targeting of mTOR with an mTOR inhibitor (rapamycin
analog) has shown tumor growth inhibition in several PDAC
cell lines (Asano et al., 2005; Hezel et al., 2006). Additionally,
rapamycin has been shown to inhibit PDAC xenograft growth and
metastasis (Bruns et al., 2004). The possiblemechanisms by which
these agents work include induction of endothelial cell death and
tumor vessel thrombosis (Bruns et al., 2004). A phase II study
by Wolpin et al examined the use of everolimus in gemcitabine-
refractory, metastatic PDAC patients. Single-agent everolimus
was well-tolerated, but showed minimal clinical activity with no
clear evidence of treatment response, only 21% of patients having
stable disease at 2 months, a median PFS of 1.8 months, and an
overall survival of 4.5 months (Wolpin et al., 2009).
Dramatic tumor shrinkage was noted in a recent mutated
KRAS lung cancer model when treated with a combination of
a dual PI3K/mTOR inhibitor and a MEK (MAP/ERK kinase)
inhibitor (Engelman et al., 2008). This provides preclinical
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feasibility of the concept that targeting KRAS surrogates and
downstream targets is potentially a feasible therapeutic strategy.
As a result, numerous IV and oral PI3K and MEK inhibitors are
in various stages of clinical development and testing (Phase I and
II) (Engelman et al., 2008; Ying et al., 2011; Britten, 2013). Given
the known cooperation between oncogenic KRAS and PTEN defi-
ciency in PDAC tumorigenesis, further investigation is validated
for combined therapies with MEK inhibitors and PI3K or NF-kB
inhibitors. This concept of combination therapies with multiple
targets is further supported by the poor results seen in Phase
I/II studies of single-agent MEK inhibitors (CI-1040, selume-
tinib), which have shown minimal clinical response and only
a marginal improvement in median survival when used alone
(Rinehart et al., 2004; Lorusso et al., 2005; Bodoky et al., 2012;
Britten, 2013).
GROWTH FACTOR INHIBITION
The epidermal growth factor receptor (EGFR), which consists of 4
separate receptors [HER1 (ErbB-1), HER-2/Neu (ErbB-2), HER-
3 (ErbB-3), and HER-4 (ErbB-4)], is overexpressed and plays a
distinct role in PDAC (Koorstra et al., 2008). HER-2/neu over-
expression is most prominent in well-differentiated PDAC and
early-stage precursor lesions, and appears to correlate with degree
of dysplasia in the latter (Koorstra et al., 2008). In PDAC, HER-
2/neu amplification has been observed in 10–60% of patients.
(Stoecklein et al., 2004; Talar-Wojnarowska and Malecka-Panas,
2006; Koorstra et al., 2008). This gene amplication is of interest
as it could potentially be a target of trastuzumab, the monoclonal
antibody directed against the HER2/neu receptor. (Koorstra et al.,
2008). In addition, increased levels of fibroblast growth factor
(FGF), FGF-receptor, insulin-like growth factor I (IGF-I), IGF-
I receptor, nerve growth factor, and vascular endothelial growth
factor (VEGF) have also been reported in PDAC. Targeted ther-
apies directed toward several of these growth factors have been
examined with some under active clinical investigation, as noted
below (Koorstra et al., 2008).
EGFR
Despite the complexity of the EGFR signaling cascade, which is
known to provide a multitude of resistance mechanisms to EGFR-
targeted agents in PDAC, the small molecule tyrosine kinase
inhibitor (TKI) of EGFR, erlotinib, has been approved in the US.
Moore et al conducted a phase III double-blind study randomiz-
ing patients with advanced PDAC to gemcitabine with or without
erlotinib. A small but statistically significant improvement in PFS,
one-year OS, andmedian OS was seen (Bruns et al., 2000; Li et al.,
2004b; Ducreux et al., 2007; Moore et al., 2007). Interestingly,
the subset of patients who developed erlotinib-related skin tox-
icity had a significantly more profound clinical response. It has
been hypothesized that these results may be due to a decrease in
tumor vasculature mediated through endothelial apoptosis, given
that EGFR is expressed not only on tumor cells but also on divid-
ing endothelial cells (Bruns et al., 2000; Li et al., 2004b; Ducreux
et al., 2007). Furthermore, the effect of erlotinib may also poten-
tially be due to inhibition of proangiogenic factors (VEGF, IL-8)
by EGFR inhibitors, given that activation of the EGF receptor on
tumor cells is known to induce the production of VEGF (Bruns
et al., 2000; Li et al., 2004b; Ducreux et al., 2007). Attempts
to correlate expression of molecular targets, such as EGFR, to
outcomes in erlotinib-based therapies have been unsuccessful to
date (da Cunha Santos et al., 2010). EGFR expression as quanti-
fied by immunohistochemistry techniques is unlikely to identify
those tumors predominantly driven by the EGFR signaling path-
way and thus would potentially be responsive to EGFR inhibition
(Philip et al., 2010). A phase III study investigated the addition
of cetuximab to gemcitabine in an unselected patient popula-
tion (not selected for presence of EGFR mutations) and found
no significant improvement in overall or progression-free sur-
vival observed relative to gemcitabine alone (Ducreux et al., 2007;
Philip et al., 2010). Ongoing and future research focusing on iden-
tification of molecular predictors of resistance and sensitivity to
EGFR blockade will potentially improve our understanding of
such therapies and selected patient response (Philip et al., 2010).
SMAD4/DPC4
Iacobuzio-Donahue et al recently reported on Smad4 as a poten-
tial predictor of local vs. distant failure using rapid autopsy
specimen of patients with PDAC (Iacobuzio-Donahue et al.,
2009). Interestingly, intact Smad4 immunolabeling strongly cor-
related with a locally destructive phenotype (p = 0.007) and
cause of death was attributed to local progression in 30% of
patients. In a prospective single arm study of locally advanced
PDAC patients treated with induction cetuximab, gemcitabine,
and oxaliplatin followed by cetuximab, capecitabine, and radio-
therapy, Crane et al similarly found Smad4 expression correlated
with local rather than distant disease progression and potentially
represented a predictive biomarker (Crane et al., 2011). Based
on these results, RTOG 1201 is currently randomizing patients
to upfront gemcitabine followed by high-intensity capecitabine-
based IMRT (63.0Gy) vs. upfront gemcitabine followed by stan-
dard intensity capecitabine-based 3D-CRT (50.4Gy) vs. upfront
FOLFIRINOX followed by standard intensity capecitabine-based
3D-CRT (50.4Gy) and stratifying patients for intensification of
local therapy based on Smad4 status (NCT01921751).
VEGF
It is well-known that VEGF and VEGFR are frequently over-
expressed in PDAC. Disruption of VEGF signaling and tumor
angiogenesis using soluble VEGFR, VEGF high-affinity binding
chimeras, anti-VEGFmonoclonal antibodies (e.g., bevacizumab),
and ribozymes have shown strong antitumor activity in PDAC
mouse xenografts and cultured pancreatic cancer cell lines (Hezel
et al., 2006; Koorstra et al., 2008). Unfortunately, clinical results
have been disparate. Kindler et al conducted a single arm phase II
study investigating the addition of bevacizumab to gemcitabine in
patients with advanced PDAC and noted a promising median OS
of 8.8 months, PR of 21%, and SD of 46% (Kindler et al., 2005).
The follow up CALGB phase III placebo-controlled study ran-
domized patients to gemcitabine with or without bevacizumab
and found no statistically significant improvement in clinical out-
comes (Kindler et al., 2010). Similar disappointing results have
been noted with small molecule TKI of VEGFR1-3, axitinib.
(Spano et al., 2008). In addition, based on the enhanced radiosen-
sitization seen with the addition of bevacizumab to 5-FU-based
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radiotherapy in rectal cancer, similar strategies for radiosensitiza-
tion could be considered in the treatment of PDAC (Willett et al.,
2006; Ducreux et al., 2007). A phase I study evaluating the safety
of bevacizumab with concurrent capecitabine-based radiotherapy
in locally advanced PDAC initially showed bevacizumab-related
GI toxicity of duodenal mucosal ulceration, bleeding, and perfo-
ration, with protocol mandated dose reductions in capecitabine
required in 43% of patients, thus concluding that further study
of bevacizumab with chemoradiotherapy was indicated (Crane
et al., 2006). A future therapeutic target may be the VEGF-C,
a regulator of lymphangiogenesis, which is noted to be overex-
pressed in PDAC, andmay contribute to the lymphatic spread and
metastasis that are commonly seen in pancreatic cancer (Hezel
et al., 2006).
IGF-I
Elevated expression of IGF-I has been noted in PDAC tumor
cells and their surrounding stroma (Hezel et al., 2006). In addi-
tion, there is aberrant activation and constitutive overexpression
of the IGF-I receptor (IGF-IR) in approximately 64% of pan-
creatic tumor cells (Bergmann et al., 1995; Hakam et al., 2003;
Ouban et al., 2003; Stoeltzing et al., 2003; Hezel et al., 2006).
Furthermore, in a particular PDAC cell line, aberrant expres-
sion and activation of IGF-IR via paracrine and autocrine IGF-I
signaling was noted to promote cell proliferation and growth-
factor-independent survival (Nair et al., 2001). Therefore, inhi-
bition of this pathway using anti-IGF-IR antibodies or expression
of truncated IGF-I receptors (via recombinant adenovirus tech-
nique) that function as a dominant-negative form of IGF-IR has
been examined in the preclinical setting and shown to inhibit
the growth of xenograft tumors by up-regulating stressor induced
apoptosis, blocking IGF-I and IGF-II induced activation of AKT-
1, as well as sensitizing tumor cells to chemotherapy (Maloney
et al., 2003; Min et al., 2003; Hezel et al., 2006). Given the encour-
aging preclinical results, several phase I and II studies of IGF-IR
monoclonal antibody and small molecule agents have been pur-
sued (Carboni et al., 2009; Hewish et al., 2009; Kindler et al.,
2012). Kindler et al performed a randomized phase II study of
ganitumab (AMG 479; monoclonal antibody antagonist of IGF-
IR) and gemcitabine vs. gemcitabine and placebo in previously
untreated metastatic PDAC. The ganitumab arm demonstrated
acceptable toxicity, as well as trends toward improved 6- and 12-
month survival, PFS, and overall survival. Given these favorable
results, a randomized Phase III study of AMG 479 and gemc-
itabine in metastatic pancreatic adenocarcinoma was pursued,
randomizing patients to AMG 479 (12 or 20mg/kg) and gemc-
itabine vs. placebo and gemcitabine. Unfortunately, this study was
stopped early for futility based on pre-planned interim analysis
(NCT01231347).
FUTURE DIRECTIONS/SCREENING
While screening of the general population is not practicable with
current diagnostic methods, studies are ongoing to evaluate its
usefulness in people with at least 5- to 10-fold increased risk
of PDAC. This would include patients with FPC or carriers of
a mutation in an established high-penetrance PDAC suscepti-
bility gene (e.g., BRCA2 or PALB2) with at least one case of
pancreatic cancer in a first-degree relative (Brand et al., 2007;
Bartsch et al., 2012; Klein, 2012; Canto et al., 2013). Furthermore,
it has been suggested that such individuals undergo screening
for any extrapancreatic tumors associated with their respective
germline mutation prior to the development of any respective
clinical symptomatology.
USPSTF Screening Guidelines for PDAC have been given a
D recommendation indicating harm outweighing any potential
benefit and recommending against routine screening in asymp-
tomatic adults using abdominal palpation, ultrasonography, or
serologic markers. International Cancer of the Pancreas Screening
(CAPS) Consortium summit recommendations for PDAC con-
cluded that screening is recommended for high-risk individuals,
although more evidence is needed regarding optimal manage-
ment of patients with detected lesions. These high-risk candidates
for screening include first degree relatives of patients with PDAC
from familial kindred with at least two affected first-degree rela-
tives, patients with PJS, and carriers of p16, BRCA2, or HNPCC
mutations with at least one affected first-degree relative. The
CAPS Consortium was not able to reach a consensus on the
age to initiate screening or stop surveillance, as well as screen-
ing intervals, although agreement was made that initial screening
should include EUS and/or MRI/MRCP, and not CT or ERCP
(Canto et al., 2013). At this time, based on the current knowl-
edge of pancreatic susceptibility genes, affected patients of FPC
families should consider being tested for the most frequently
inherited genetic defects identified in FPC, BRCA2, PALB2, and
ATM germline mutations. The use of PDAC biomarkers, such as
CA-19-9 and CEACAM-1, have not yet been validated for clinical
use in screening (Bussom and Saif, 2010).
To help identify high-risk populations who would be most
likely to benefit from early detection screening tests, discov-
ery of additional pancreatic cancer susceptibility genes is crucial
(Brentnall et al., 1999; Canto et al., 2006; Koorstra et al., 2008;
Vasen et al., 2011; Klein, 2012). Gene expression patterns in serum
and tissue biopsies can be studied using whole-genome assay-
ing, including technologies such serial analysis of gene expres-
sion (SAGE), cDNA arrays, and oligonucleotide arrays (i.e., gene
chips) (Maitra et al., 2006). Further, specific gene-based, gene-
product, and marker-based testing for the early detection of pan-
creatic cancer are currently being developed, which may include
miRNAs, whichmay also be useful as potential therapeutic targets
as well (Koorstra et al., 2008).
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